Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
November 30, 2023 02:00 ET
|
Zealand Pharma
Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no....
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
November 16, 2023 16:00 ET
|
Zealand Pharma
Company announcement – No. 39 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, November 16, 2023 – Zealand Pharma...
Zealand Pharma Announces Financial Results for the First Nine Months of 2023
November 09, 2023 01:00 ET
|
Zealand Pharma
Company announcement - No. 38 / 2023 Zealand Pharma Announces Financial Results for the First Nine Months of 2023 Strong progress across obesity pipeline, first PDUFA date for...
Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023
November 07, 2023 04:00 ET
|
Zealand Pharma
Press release – No. 15 / 2023 Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023 Copenhagen, Denmark, November 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL)...
Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results
November 03, 2023 12:00 ET
|
Zealand Pharma
Press Release – No. 14 / 2023 Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results Copenhagen, Denmark, November 3, 2023 – a Zealand...
Zealand Pharma major shareholder announcement: Polar Capital
October 20, 2023 16:00 ET
|
Zealand Pharma
Company announcement – No. 37 / 2023 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 20 October 2023 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20...
Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek
October 17, 2023 02:00 ET
|
Zealand Pharma
Press release – No. 13 / 2023 Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek Copenhagen, Denmark, October 17, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no....
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
October 05, 2023 05:53 ET
|
Zealand Pharma
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease Press release – No. 12 /...
Total number of shares and voting rights in Zealand Pharma at September 29, 2023
September 29, 2023 11:15 ET
|
Zealand Pharma
Company announcement – No. 36 / 2023 Total number of shares and voting rights in Zealand Pharma at September 29, 2023 Copenhagen, Denmark, September 29, 2023 – Zealand Pharma A/S (“Zealand”)...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
September 14, 2023 16:30 ET
|
Zealand Pharma
Company announcement – No. 35 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...